Boehringer Ingelheim Collaborates with Walgreens to Improve Clinical Trials Access
Shots:
- Boehringer Ingelheim has collaborated with Walgreens to enhance clinical trial recruitment, aiming for accessibility and inclusivity. The P-III study opportunities will be offered in Walgreens pharmacies
- The collaboration will utilize Walgreens community pharmacies as study sites for obesity, overweight & type 2 diabetes, thus improving access and addressing equitable health representation in clinical trials. Walgreens will identify and engage patients using advanced, real-world insights
- BI also teams up with EmVenio Research to introduce mobile research units for better reach and clinical trial participation
Ref: Boehringer Ingelheim | Image: Boehringer Ingelheim
Related News:- The US FDA Approves High Concentration of Boehringer Ingelheim's Cyltezo (Biosimilar, Humira)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
